CHMP meets to discuss Multaq
News
The Committee for Medicinal Products for Human Use (CHMP) met on Friday 2 September 2011 to discuss the ongoing benefit-risk review of the anti-arrhythmic medicine Multaq (dronedarone).
The Committee discussed all of the currently available data on the risk of cardiovascular problems, liver and lung injuries reported with the use of Multaq in order to prepare for its next scheduled meeting of 19-22 September 2011, when it expects to finalise its review.